Terozin

Terazosin hydrochloride.

Each tablet contains: Terazosin (as hydrochloride) 2 mg & 5 mg.
Terazosin is an alpha₁ adrenoceptor blocker with actions similar to those of prazosin but a longer duration of action. It is used in the management of hypertension and in benign prostatic hyperplasia to relieve symptoms of urinary obstruction.

Pharmacology: Pharmacokinetics: Terazosin is rapidly and almost completely absorbed from the gastrointestinal tract after oral administration; the bioavailability is reported to be about 90%. Peak plasma concentrations are achieved in about one hour. It is metabolized in the liver; one of the metabolites is reported to possess antihypertensive activity. The half-life in plasma approximately 12 hours. It is excreted in feces via the bile, and in the urine as unchanged drug and metabolites. Terazosin is 90 to 94% protein bound.

It is used for the treatment of mild to moderate hypertension and in benign prostatic hyperplasia.

After oral doses its hypotensive effects are seen within 15 minutes and may last for up to 24 hours, permitting once daily. To avoid the risk of collapse which may occur in some patients after the first dose the initial dose for both hypertension and benign prostatic hyperplasia is 1 mg of Terazosin at bedtime, increasing gradually at intervals of 7 days according to patients response.
For hypertension, the usual maintenance dose is 2 to 10 mg once daily and maximum dose is 20 mg daily in a single dose or two divided doses. For benign prostatic hyperplasia, the usual maintenance dose is 5-10 mg daily or as prescribed by physician.

May produce reflex stimulation of the sympathetic system resulting in tachycardia and may provoke acute coronary attacks in patients with known significant coronary artery disease or with angina pectoris and giddiness.

Treatment with terazosin should be introduced cautiously because of the risk of sudden collapse following the initial dose. Special caution is necessary to patients with renal or hepatic impairment and in the elderly. Terazosin should be used with caution in patients with angina pectoris. It may cause drowsiness or dizziness; patients so affected should not drive or operate machinery.
Terazosin is not recommended for the treatment of heart failure caused by mechanical obstruction, for example aortic/mitral valve stenosis, pulmonary embolism and restrictive pericardial disease.

The most common side effects include dizziness, drowsiness, headache, lack of energy, nausea and palpitations and may diminish with continuous terazosin therapy or with a reduction in dosage. Other adverse effects include edema, chest pains, dyspnea, constipation, diarrhea, vomiting, depression and nervousness, sleep disturbances, vertigo, hallucinations, paraesthesia, nasal congestion, epistaxis, dryness of mouth, urinary frequency and incontinence, reddened sclera, blurred vision, tinnitus, abnormal liver enzyme values, pancreatitis, arthralgia, alopecia, lichen planus, skin rashes, pruritus and diaphoresis. Impotence and priapism have also been reported.
Terazosin hydrochloride can cause orthostatic hypotension which may be severe and produce syncope after initial dose; it may be preceded by tachycardia. This reaction can be avoided by starting treatment with a low dose, preferably at night. The hypotensive effects may be exaggerated by exercise, heat or alcohol ingestion.

The hypotensive effects of terazosin may be enhanced by the concomitant administration of diuretics and other antihypertensives, and by alcohol and other drugs that cause hypotension. The risk of first-dose hypotension may be particularly increased in patients receiving beta blockers or calcium-channel blockers.

Store at temperatures not exceeding 30°C.

Drugs for Bladder & Prostate Disorders / Other Antihypertensives

G04CA03 - terazosin ; Belongs to the class of alpha-adrenoreceptor antagonists. Used in the treatment of benign prostatic hypertrophy.

Rx